AN ADVISORY committee of the Food and Drug Administration has taken the first steps toward selecting the strains of virus to be included in next year's influenza vaccine.
After considering data on disease surveillance, antigenic composition of the influenza-virus strains in circulation, and the efficacy of the current vaccine, the group held off making a final decision on the 2 A-type viruses. However, panel members agreed unanimously to leave unchanged for next year the B constituent of the vaccine, known as B/Harbin/07/94.
Marwick C. As Flu Season Ends, Vaccines for Next Considered. JAMA. 1998;279(10):738. doi:10.1001/jama.279.10.738-JMN0311-5-1